AI-Driven Vaccine Partnerships And Dark Genome Targets Will Shape Long-Term Opportunity

AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

15 Dec 25

Updated

26 Jun 26

Views

Not Invested

Shared on 26 Jun 26

Fair value Decreased 21%

EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential

Evaxion shares new early lab results for its cancer vaccine programs, including work aimed at hard-to-treat blood cancer and brain cancer, plus an ongoing personalized cancer vaccine study. While the science updates keep coming, expectations cool a bit as analysts trim what they think the company is worth based on more cautious growth and profit assumptions.

10 views

Fair Value vs Share Price

US$11.25

vs US$3.2171.5% undervalued

72.3%

Revenue growth

18.9%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Evaxion

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Excellent balance sheet with slight risk.

Market capUS$25.6m

PB2.0x

Estimated Growth28.0%

Dividend YieldN/A

Full analysis

CEO & management

Helen Tayton-Martin

CEO

3.3yrs

CEO Tenure

A clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.